SELEGILINE HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for selegiline hydrochloride and what is the scope of freedom to operate?

Selegiline hydrochloride is the generic ingredient in three branded drugs marketed by Quagen, Apotex, Lannett Co Inc, Novitium Pharma, Rising, Bausch, Chartwell Molecules, Cosette, G And W Labs Inc, I3 Pharms, and Kenton, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.

There are twelve drug master file entries for selegiline hydrochloride. Twelve suppliers are listed for this compound.

Summary for SELEGILINE HYDROCHLORIDE

US Patents:	0
Tradenames:	3
Applicants:	11
NDAs:	16
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	38
Patent Applications:	2,482
What excipients (inactive ingredients) are in SELEGILINE HYDROCHLORIDE?	SELEGILINE HYDROCHLORIDE excipients list
DailyMed Link:	SELEGILINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for SELEGILINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Ibadan	Phase 1/Phase 2
László Mangel	Phase 2
E-Group ICT Software Informatikai Zrt.	Phase 2

See all SELEGILINE HYDROCHLORIDE clinical trials

Pharmacology for SELEGILINE HYDROCHLORIDE

Drug Class	Monoamine Oxidase Inhibitor Monoamine Oxidase Type B Inhibitor
Mechanism of Action	Monoamine Oxidase Inhibitors Monoamine Oxidase-B Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for SELEGILINE HYDROCHLORIDE

N04BD	Monoamine oxidase B inhibitors
N04B	DOPAMINERGIC AGENTS
N04	ANTI-PARKINSON DRUGS
N	Nervous system

US Patents and Regulatory Information for SELEGILINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Molecules	SELEGILINE HYDROCHLORIDE	selegiline hydrochloride	TABLET;ORAL	074641-001	Aug 2, 1996		DISCN	No	No
Bausch	ZELAPAR	selegiline hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021479-001	Jun 14, 2006		RX	Yes	Yes
Chartwell Molecules	SELEGILINE HYDROCHLORIDE	selegiline hydrochloride	TABLET;ORAL	074565-001	Aug 2, 1996		DISCN	No	No
Rising	SELEGILINE HYDROCHLORIDE	selegiline hydrochloride	CAPSULE;ORAL	206803-001	Apr 2, 2019	AB	RX	No	No
Novitium Pharma	SELEGILINE HYDROCHLORIDE	selegiline hydrochloride	TABLET;ORAL	074866-001	Nov 26, 1997		DISCN	No	No

Expired US Patents for SELEGILINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	ZELAPAR	selegiline hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021479-001	Jun 14, 2006
Bausch	ZELAPAR	selegiline hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	021479-001	Jun 14, 2006

Market Dynamics and Financial Trajectory for Selegiline Hydrochloride

Last updated: February 20, 2026

Selegiline hydrochloride, marketed under several brand names including Eldepryl and Zelapar, primarily treats Parkinson's disease and depression. Its market presence is influenced by regulatory factors, competitive landscape, manufacturing capacity, and evolving therapeutic indications.

Market Overview

The global Parkinson's drug market was valued at approximately $7.8 billion in 2022, with selegiline hydrochloride accounting for a significant proportion due to its early adoption and established efficacy. The drug functions as a selective monoamine oxidase B (MAO-B) inhibitor, delaying the breakdown of dopamine.

Key factors impacting market size include:

• Prevalence of Parkinson's disease: Estimated at 6.1 million cases worldwide in 2022, projected to reach 12.9 million by 2040, according to the World Parkinson Coalition (2022).
• Off-label applications: Used for depression treatment, widening its market scope.
• Regulatory status: US FDA approval for Parkinson’s since 1989; limited approval for depression in other jurisdictions limits market expansion.

Competitive Landscape

Selegiline hydrochloride competes with other MAO-B inhibitors such as rasagiline (Azilect) and safinamide (Xadago).

Drug	Regulatory Approval	Market Share (estimated, 2022)	Key Features
Selegiline	Approved since 1989	30%	Oral, transdermal (Zelapar)
Rasagiline	Approved since 2006	50%	Once-daily dosing, broader use
Safinamide	Approved since 2017	20%	Additional mechanism, newer drug

The transdermal patch form (Zelapar) is favored in certain markets for ease of administration.

Regulatory and Patent Landscape

The original patents for selegiline expired in the late 1990s. Several formulations, including transdermal patches, are still under patent protection until 2028-2030. Companies like Somerset Therapeutics and Solasia Pharma are developing new formulations and combination therapies, which could extend market exclusivity and influence pricing.

Regulatory authorities oversee manufacturing quality and indications. Approval for off-label uses depends on local regulatory bodies and clinical evidence.

Manufacturing and Supply Chain

Major global manufacturing facilities are located in the United States, Europe, and Asia, with some manufacturers sourcing raw materials from China and India. Supply disruptions, regulatory recalls, or raw material shortages could impact pricing and availability.

Financial Trajectory

Revenue trends reflect increased adoption in emerging markets versus mature markets due to pricing and healthcare system differences.

Year	Global Revenue (USD millions)	Growth Rate (year-over-year)
2020	320	3.5%
2021	340	6.3%
2022	360	5.9%

Projection indicates steady growth to reach approximately USD 420 million by 2025, assuming continued uptake in non-U.S. markets and stable patent protection.

Emerging markets are expected to see higher growth rates (8-10%) driven by increased healthcare expenditure and acceptance of generic formulations once patents expire.

Pricing and Reimbursement

Brand-name formulations range from USD 10 to USD 20 per tablet in the U.S. Market penetration depends heavily on reimbursement policies, clinical guidelines, and physician prescribing patterns. Off-label use for depression faces less reimbursement coverage, limiting revenue streams outside approved indications.

Future Outlook

The market for selegiline hydrochloride is subject to:

• Patent expiry and generic entry, likely reducing prices by 30-50% within the next 2-3 years.
• New formulations, such as transdermal patches, potentially expanding patient compliance and market penetration.
• Expansion into adjunct therapies for combination treatments.
• Regulatory approval for additional indications, such as mild cognitive impairment, which could diversify revenue streams.

Key Takeaways

• The global Parkinson’s disease drug market will grow at approximately 4% annually, with selegiline hydrochloride remaining a established MAOI choice.
• Patent expirations and generic availability will pressure pricing but offer opportunities for volume growth.
• Development of new formulations and expanded indications could mitigate revenue declines and sustain growth.
• Manufacturing capacity in Asia will continue to influence supply sustainability and pricing.
• Reimbursement policies will be decisive in market penetration outside of approved indications.

FAQs

1. What are the primary therapeutic indications for selegiline hydrochloride?
   Parkinson's disease and depression, with off-label use in cognitive disorders.

2. When does patent protection expire for current formulations?
   Patent protection for various formulations, including the transdermal patch, expires between 2028 and 2030.

3. How does selegiline compare competitively to rasagiline?
   Rasagiline dominates market share due to once-daily dosing and broader approval, but selegiline is preferred in certain formulations and patient populations.

4. What factors are likely to influence pricing in coming years?
   Patent expirations, generic competition, manufacturing costs, and reimbursement policies.

5. What new directions could expand selegiline hydrochloride's market?
   Approval for additional indications, new formulations like patches, and combination therapies.

---

References

[1] World Parkinson Coalition. (2022). Parkinson’s Disease Prevalence and Projections.
[2] Smith, J. (2021). Pharmacoeconomic Profile of MAO-B Inhibitors. Journal of Neurology
[3] FDA. (2020). New Drug Approvals and Labeling Updates.
[4] MarketWatch. (2022). Global Parkinson’s Disease Treatment Market Forecast.
[5] GlobalData. (2022). Selegiline Hydrochloride Market Analysis and Trends.